RenaSci offers the choline deficient (CD) diet mouse model of NASH and fibrosis. This model was developed as a refinement of the methionine and choline deficient (MCD) diet mouse. The MCD mouse has the disadvantage of inducing ~40% weight loss over 6 weeks. This is in contrast to the ~15% reduction in body weight observed in the CD mouse.
Mice are maintained on the CD diet for 6 weeks. Resulting in increases in the following parameters:
RenaSci’s CD mouse has been validated with the peroxisome proliferator activated receptor (PPAR) gamma agonist, pioglitazone, and the dual PPAR alpha/delta agonist, elafibranor. These drugs have efficacy in the clinic to improve NASH and have reduced or inhibited many of the features of NASH and fibrosis in the CD mouse.
These results demonstrate that RenaSci’s CD mouse can be used as a simple, short-term (6 weeks) model to identify compounds with potential for the treatment of NASH and fibrosis.
Representative images of sirius red stained liver sections, magnification x10 demonstrating the difference between
the vehicle, CD diet, Pioglitazone 15 mg/kg po bid and Elafibranor 30/20 mg/kg po qd groups.
This graph demonstrates body weight against time for the vehicle, CD diet, Pioglitazone 15 mg/kg po bid and Elafibranor 30/20 mg/kg po qd groups.
Explore our other models of NASH
For more details or information on how we can support your project please complete the contact form.